real-world results of an in-class transition from vrd to ird in myeloma
Published 3 years ago • 45 plays • Length 2:01Download video MP4
Download video MP3
Similar videos
-
1:30
outcomes in rrmm treated with ird in the real world
-
3:56
real-world analysis of treatment patterns and outcomes in newly diagnosed myeloma
-
1:43
real-world outcomes of teclistamab for r/r multiple myeloma
-
2:12
results from phase i study of alnuctamab administered intravenously & subcutaneously in r/r myeloma
-
2:25
the importance of real-world data in multiple myeloma
-
7:51
real-world data and its real-world use
-
9:36
what are the real-world outcomes following treatment with teclistamab in rrmm?
-
10:49
mayo clinic rochester
-
1:30
real-world insight for myeloma
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
2:43
the importance of reporting real world data in myeloma
-
2:31
uk practice: pomalidomide in patients resistant to lenalidomide
-
2:02
rwd from insight-mm: duration of therapy and treatment sequencing
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
3:01
treatment approaches for asct-eligible myeloma patients in the frontline
-
1:30
real-world treatment patterns in third-line therapy for r/r myeloma
-
3:52
real-world data on outcomes of t(11;14) multiple myeloma
-
2:45
myeloma: real-world data
-
3:02
real-world safety and efficacy of cilta-cel in r/r multiple myeloma
-
3:00
current & emerging biomarkers in multiple myeloma
-
1:37
mrd in myeloma